Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

ClinicalTrials.gov ID: NCT03943446

Public ClinicalTrials.gov record NCT03943446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main aim is to see if TAK-018 reduces the recurrence of intestinal inflammation after abdominal resection surgery in adults with Crohn's disease. Participants will take either TAK-018 or placebo tablets by mouth, 2 times each day for up to 26 weeks after surgery. The placebo looks like TAK-018 but will not have any medicine in it. Participants will have 6 study visits while receiving treatment. Visits 1 and 6 will be conducted at the study clinic. The others can be in the clinic or at the participant's home. Follow-up will occur 4 weeks after final treatment.

Study identification

NCT ID
NCT03943446
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Takeda
Industry
Enrollment
34 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 3, 2020
Primary completion
Aug 24, 2022
Completion
Aug 24, 2022
Last update posted
Sep 6, 2023

2020 – 2022

United States locations

U.S. sites
23
U.S. states
16
U.S. cities
19
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
Cedars-Sinai Medical Center Los Angeles California 90048
Hoag Memorial Hospital Presbyterian Los Angeles California 92618
University of Colorado Hospital Anschutz Cancer Pavilion Aurora Colorado 80045
Mayo Clinic - Jacksonville Jacksonville Florida 32224
University of Miami Leonard M. Miller School of Medicine Miami Florida 33136
University of South Florida/USF Health Tampa Florida 33612
Atlanta Gastroenterology Associates Atlanta Georgia 30342
Northwestern University Chicago Illinois 60611
The University of Chicago Medical Center Chicago Illinois 60637
University of Kentucky Chandler Medical Center Lexington Kentucky 40536
Johns Hopkins University Baltimore Maryland 21205
Massachusetts General Hospital Boston Massachusetts 02114
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire 03756
NYU Langone Inflammatory Bowel Disease Center New York New York 10016
Icahn School of Medicine at Mount Sinai New York New York 10029
Columbia University Irving Medical Center New York New York 10032
University of North Carolina School of Medicine Chapel Hill North Carolina 27599-7032
Atrium Health Charlotte North Carolina 28204
Cleveland Clinic Cleveland Ohio 44195
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213-2536
Vanderbilt Inflammatory Bowel Disease Clinic Nashville Tennessee 37212-1375
Houston Methodist Hospital Houston Texas 77030-2740

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03943446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 6, 2023 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03943446 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →